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Hyperdynamic circulation as well as increased hepatic
resistance contribute to portal hypertension in cirrhosis of
the liver [1]. Hyperdynamic circulation with increased
cardiac output, heart rate and plasma volume and de-
creased arterial blood pressure and systemic vascular
resistance are characteristic in advanced cirrhosis. Sys-
temic and splanchnic vasodilatation is pivotal for the
hyperdynamic circulation. This has prompted intense
research into a number of endogenous neurohumoral me-
diators with vasodilating properties (nitric oxide, natri-
uretic peptides, glucagon, etc.) [2, 3].
In recent years, however, mechanisms augmenting in-
trahepatic vascular resistance and thus contributing to
portal hypertension have received increasing attention. In
this respect, endothelins (ETs) are of particular interest
[4–8].
ETs are a family of 21-amino acid polypeptides with
potent vasoactive properties. ET-1 was first isolated in the
supernatant of vascular endothelial cells [8] but later syn-
thesis of both circulating isopeptides, ET-1 and ET-3, was
shown in other organs such as the gastrointestinal tract
[9]. ET-1 has mainly vasoconstrictive properties by acting
on the ETA receptor on smooth muscle cells. ET-1 binds
with lower affinity also to the ETB receptor on endothelial
cells inducing a vasodilatation by the release of NO and
prostacyclins. ET-1 exhibits a much higher affinity to the
ETA receptor than ET-3, whereas the ETB receptor exhib-
its similar affinity for both isopeptides. Vascular response
to ETs thus depends on the ratio of different receptors
which seem to vary in different vascular regions [5–8] and
can be affected by gender or culture conditions. The role
of ET-3, particularly regarding portal pressure, has not
been fully elucidated yet. Therefore, mainly ET-1 will be
covered in this article.
ET Plasma Concentration and Hepatic Release in
Cirrhosis
In patients with cirrhosis of the liver elevated arterial
and venous plasma concentrations of ET-1 and ET-3 have
been described [2, 10–16]. Interestingly, there is an in-
creased hepatosplanchnic release of ET in these patients.
Release of ET-1 (fig. 1) as well as arterial and venous plas-
ma concentrations were found to correlate with the hepat-
ic venous pressure gradient [13, 14]. These findings could
indicate augmented hepatic ET-1 synthesis in cirrhosis
and/or a role of ET-1 in the increase in portal pressure.
Indeed, in the liver of cirrhotic rats increased concentra-
tions of ET-1 protein and moreover an increased ET-
receptor density has been described [17]. Furthermore,
release of ET from isolated perfused liver as well as from
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Table 1. Synthesis of and receptors for endothelin-1 in nonparen-
chymal and parenchymal cells of the liver
Synthesis Receptors
Sinusoidal endothelial cells Hepatic stellate cells
Hepatic stellate cells 11 Sinusoidal endothelial cells 11
Kupffer cells Kupffer cells
Hepatocytes
sinusoidal endothelial cells upon stimulation by trans-
forming growth factor-ß have been observed [18, 19].
These findings raise the question as to which cells of the
liver synthesize ET and whether this is stimulated in liver
damage or cirrhosis.
ET Synthesis in Various Cell Types of the Liver
Expression of ET-1 in isolated liver cells was detected
mainly in sinusoidal endothelial cells and stellate cells and
to a lesser extent in Kupffer cells (table 1). Following liver
injury by bile duct ligation, prepro ET-1 mRNA increased
mainly in stellate cells and to a lesser extent in endothelial
cells [20]. These data support the finding of ET-1 overex-
pression in stellate cells and sinusoidal endothelial cells of
human cirrhotic liver [21]. Hepatic stellate cells are
located in the space of Disse and surround the sinusoidal
capillary composed of endothelial cells and Kupffer cells.
This anatomic location suggests a role of stellate cells in
the regulation of the diameter of liver sinusoids and thus
of portal pressure possibly by endocrine or paracrine
effects.
ET Effects on Various Cells of the Liver
ET receptors have been found mainly on stellate cells
and sinusoidal endothelial cells, but also on Kupffer cells
and hepatocytes (table 1) [22–24]. As shown recently, the
ET-induced decrease in the hepatic microvascular blood
flow is predominantly mediated by the contraction of stel-
late cells [23, 25–27]. Furthermore, recent evidence sug-
gests an effect of ET on hepatic microvascular exchange in
cirrhosis, possibly by affecting the fenestration of sinusoi-
dal endothelial cells [28]. This might be another mecha-
nism contributing to a decrease of hepatic function in cir-
rhosis.
Fig. 1. Hepatosplanchnic release of endothelin-1 in patients with
cirrhosis is related to the degree of portal hypertension as indicated
by the hepatic-venous pressure gradient. Data adapted from Gerbes
et al. [13].
ET and Portal Pressure
ET causes an increase of portal pressure in vivo as well
as in isolated perfused liver [29, 30]. In cirrhotic liver, but
not in controls, portal pressure decreases upon adminis-
tration of an ET-receptor antagonist [31]. These data sug-
gest a role of ET in modulating portal pressure, particu-
larly in portal hypertension. In liver injury or cirrhosis as
well as with ischemia-reperfusion injury, there is Kupffer
cell activation as well as an increase in portal pressure.
Interestingly, the activation of Kupffer cells seems to con-
tribute to the increase of portal pressure. This is partly
mediated by ET as was recently shown in isolated per-
fused rat liver [32].
Conclusions
Plasma concentrations of ETs are increased in cirrho-
sis which may be due to increased hepatosplanchnic
release. This could reflect increased hepatic synthesis of
ET-1, mainly by stellate and sinusoidal endothelial cells.
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ET increases portal pressure, and ET-receptor blockade
decreases portal hypertension in cirrhosis. ET also seems
an important mediator of the increase in portal pressure
upon Kupffer cell stimulation. Thus, ET modulates portal
pressure and is involved in the pathophysiology of portal
hypertension.
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